Pembrolizumab (MK-3475), a monoclonal antibody targeting PD-1 on T cells, enhances immune responses by blocking the interaction between PD-1 on T cells and its ligand, PD-L1, found on tumor cells [48,52-54]. Here, PDCD1 is linked to neoplasm.